Analyst ratings are aggregated from multiple third-party sources and may be inaccurate, incomplete, or outdated. All ratings remain the sole responsibility of their original providers. Rankings are based on the 3-year performance of a simulated $100,000 account trading on analyst ratings data.
| Trades 674 | Longs Won 419/673 62% | Profit Factor 1.39 |
| Profitability | Shorts Won 0/1 0% | Standard Deviation $1,950.28 |
| Average Win $391.36 | Best Trade (Dec 09) $13,207.72 | Sharpe Ratio -196.86 |
| Average Loss -$462.92 | Worst Trade (Oct 12) -$42,833.56 | Z-Score -8.98 (100%) |
| Commissions $0 | Avg. Trade Length 2m 1w 3d | Expectancy $68.15 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | 0.02% | 0.19% | 0.86% | 2.73% | 7.04% | 15.68% | 31.38% | 57.85% |
| Consecutive Losing Trades | 315 | 284 | 252 | 221 | 189 | 158 | 126 | 95 | 63 | 32 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
PVLA Pavella Therapeutics Inc. | 1,148 | $154,268.18 | $138,282.28 | - | -$15,985.9 | -10.36% | -5.407% |